ALNY - Alnylam Pharmaceuticals Inc. (ALNY) Q1 2024 Earnings Call Transcript

2024-05-02 12:15:23 ET

Alnylam Pharmaceuticals, Inc. (ALNY)

Q1 2024 Earnings Conference Call

May 2, 2024 8:30 AM ET

Company Participants

Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communications

Yvonne Greenstreet – Chief Executive Officer

Tolga Tanguler – Chief Commercial Officer

Pushkal Garg – Chief Medical Officer

Jeff Poulton – Chief Financial Officer

Conference Call Participants

David Lebowitz – Citi

Paul Matteis – Stifel

Maury Raycroft – Jefferies

Gary Nachman – Raymond James

Tazeen Ahmad – BofA Securities

Ritu Baral – TD Cowen

Jessica Fye – JPMorgan

Kostas Biliouris – BMO Capital Markets

Ellie Merle – UBS

Gena Wang – Barclays

Mike Ulz – Morgan Stanley

Whitney Ijem – CG

Presentation

Operator

Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Quarter One 2024 Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a Q&A session. [Operator Instructions] Please be advised that today’s conference is being recorded.

And I would now like to hand the conference over to the company for their remarks. Please go ahead.

Christine Lindenboom

Good morning. I’m Christine Lindenboom, Senior Vice President, Investor Relations and Corporate Communications at Alnylam. With me today are Yvonne Greenstreet, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Pushkal Garg, Chief Medical Officer; and Jeff Poulton, Chief Financial Officer.

For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, investors.alnylam.com/events. During today’s call, as outlined in Slide 2, Yvonne will offer introductory remarks and provide general context. Tolga will provide an update on our global commercial progress. Pushkal will review pipeline updates and clinical progress and Jeff will review our financials and guidance, followed by a summary of upcoming milestones before we open the call to your questions.

I would like to remind you that this call will contain remarks concerning Alnylam’s future expectations, plans and prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent periodic report on file with the SEC....

For further details see: